{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:33:44Z","timestamp":1790472824686,"version":"4.1.0"},"reference-count":184,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015756","name":"Spanish Society of Infectious Diseases and Clinical Microbiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.trre.2025.100937","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:23:53Z","timestamp":1747826633000},"page":"100937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESITRA-IC\/SEIMC, CIBERINFEC, and SET recommendations update."],"prefix":"10.1016","volume":"39","author":[{"given":"Isabel","family":"Rodr\u00edguez-Goncer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ruiz-Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Sab\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibai","family":"Los-Arcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Tiago","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"P\u00e9rez-Nadales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Machuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricela","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Cast\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bodro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purificaci\u00f3n","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Mar\u00eda","family":"Cruzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantino","family":"Fondevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Fort\u00fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dolores","family":"Garc\u00eda-Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Guti\u00e9rrez-Dalmau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Iturbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago","family":"Justo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Len","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"L\u00f3pez-Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Ovidia","family":"L\u00f3pez Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Mart\u00edn-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auxiliadora","family":"Mazuecos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mirabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"P\u00e9rez-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Rodr\u00edguez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"San-Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"S\u00e1nchez-C\u00e9spedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Vidal Verd\u00fa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Torre-Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2025.100937_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.trre.2017.07.001","article-title":"Management of multidrug resistant gram-negative bacilli infections in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations","volume":"32","author":"Aguado","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2025.100937_bb0010","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/cid\/ciz1113","article-title":"Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss transplant cohort study","volume":"71","author":"van Delden","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0015","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Schunemann","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2025.100937_bb0020","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/bmj.39504.506319.80","article-title":"Incorporating considerations of resources use into grading recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2025.100937_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a744","article-title":"Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive","volume":"337","author":"Jaeschke","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2025.100937_bb0030","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2025.100937_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11908-016-0526-9","article-title":"Multidrug-resistant bacterial Donor-derived infections in solid organ transplantation","volume":"18","author":"Lewis","year":"2016","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.trre.2025.100937_bb0040","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1111\/ajt.13317","article-title":"Outcome of transplantation using organs from Donors infected or colonized with Carbapenem-resistant gram-negative Bacteria","volume":"15","author":"Mularoni","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0045","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cmi.2019.04.014","article-title":"The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study","volume":"25","author":"Giannella","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115220","article-title":"Surgical site infection after liver transplantation in the era of multidrug-resistant bacteria: what new risks should be considered?","volume":"99","author":"Freire","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0055","article-title":"Epidemiology and prevention of early infections by multi-drug-resistant organisms in adults undergoing liver transplant: a narrative review microorganisms","volume":"11","author":"Dolci","year":"2023"},{"key":"10.1016\/j.trre.2025.100937_bb0060","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.transproceed.2021.04.014","article-title":"Impact of Donor-derived multi-drug-resistant organism infections on abdominal solid organ transplantation recipients in China","volume":"53","author":"Xiao","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100937_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123706","article-title":"Incidence of carbapenem-resistant gram negatives in Italian transplant recipients: a nationwide surveillance study","volume":"10","author":"Lanini","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.trre.2025.100937_bb0070","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.healun.2024.04.005","article-title":"Lung donor bronchoalveolar lavage positivity: incidence, risk factors, and lung transplant recipients\u2019 outcome","volume":"43","author":"Fumagalli","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0075","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1111\/ajt.15830","article-title":"Impact of deceased donor multidrug-resistant bacterial organisms on organ utilization","volume":"20","author":"Anesi","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/1469-0691.12557","article-title":"Recommendations for screening of donor and recipient prior to solid organ transplantation and to minimize transmission of donor-derived infections","volume":"20","author":"Len","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0085","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14034","article-title":"A worldwide survey on perioperative antimicrobial prophylaxis for heart transplantation: from theory to clinical practice","volume":"25","author":"Seminari","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cmi.2018.05.003","article-title":"Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy","volume":"25","author":"Errico","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13783","article-title":"Impact of donor multidrug-resistant organisms on solid organ transplant recipient outcomes","volume":"24","author":"Anesi","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/IDR.S346494","article-title":"Prevention and treatment of Carbapenem-resistant organism Bacilli from liver transplantation Donors - single center experience","volume":"15","author":"He","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0105","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.15488","article-title":"Risk factors for multidrug-resistant organisms among deceased organ donors","volume":"19","author":"Anesi","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MOT.0000000000000991","article-title":"Deceased donors with multidrug-resistant organisms: implications and future directions","volume":"27","author":"Pouch","year":"2022","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ajt.12978","article-title":"Communication gaps associated with donor-derived infections","volume":"15","author":"Miller","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0120","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jinf.2019.12.006","article-title":"Donor-derived bacterial infections in lung transplant recipients in the era of multidrug resistance","volume":"80","author":"Bunsow","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jinf.2023.12.013","article-title":"Donor respiratory multidrug-resistant bacteria and lung transplantation outcomes","volume":"88","author":"Abdulqawi","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/ajt.16178","article-title":"Ten years of donor-derived disease: a report of the disease transmission advisory committee","volume":"21","author":"Kaul","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0135","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ajt.2024.02.005","article-title":"Donor-derived carbapenem-resistant gram-negative bacterial infections in solid organ transplant recipients: active surveillance enhances recipient safety","volume":"24","author":"Mularoni","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12743","article-title":"Successful liver transplantation despite donor-transmitted ESBL-producing Klebsiella pneumoniae infection: case report and review of the literature","volume":"19","author":"Escola-Verge","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0145","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13594","article-title":"Multidrug-resistant gram-negative bacterial infections in solid organ transplant recipients-guidelines from the American Society of Transplantation infectious diseases Community of Practice","volume":"33","author":"Pouch","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1399-3062.2012.00742.x","article-title":"Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae","volume":"14","author":"Ariza-Heredia","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0155","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1128\/JCM.00511-14","article-title":"Cross-infection of solid organ transplant recipients by a multidrug-resistant Klebsiella pneumoniae isolate producing the OXA-48 carbapenemase, likely derived from a multiorgan donor","volume":"52","author":"Giani","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2025.100937_bb0160","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.2147\/IDR.S381265","article-title":"Effect of Carbapenem-resistant Klebsiella pneumoniae infection on the clinical outcomes of kidney transplant recipients","volume":"15","author":"Zheng","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0165","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1399-3062.2011.00674.x","article-title":"Favorable outcome in a renal transplant recipient with donor-derived infection due to multidrug-resistant Pseudomonas aeruginosa","volume":"14","author":"Simkins","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13256","article-title":"Donor-derived transmission through lung transplantation of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 carbapenemase during an ongoing healthcare facility outbreak","volume":"22","author":"Bardossy","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s15010-023-02089-6","article-title":"Real-time, random-access organ screening for carbapenem-resistant organisms (CRO) reduces CRO-associated, donor-derived infection mortality in lung transplant recipients","volume":"52","author":"Zhou","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.trre.2025.100937_bb0180","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.cmi.2024.03.036","article-title":"The impact of colonization by multidrug resistant bacteria on graft survival, risk of infection, and mortality in recipients of solid organ transplant: systematic review and meta-analysis","volume":"30","author":"Almohaya","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0185","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciy199","article-title":"Genomic surveillance reveals diversity of multidrug-resistant organism colonization and infection: a prospective cohort study in liver transplant recipients","volume":"67","author":"Macesic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0190","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13646","article-title":"Isolation of antibiotic-resistant gram-negative organisms from donor respiratory culture does not impact non-lung solid organ recipient management","volume":"33","author":"Benamu","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0195","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cmi.2022.12.012","article-title":"ESCMID\/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant gram-negative bacteria before surgery","volume":"29","author":"Righi","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eimc.2019.10.016","volume":"38","author":"Len","year":"2020","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"10.1016\/j.trre.2025.100937_bb0205","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13547","article-title":"Donor-derived infections: guidelines from the American Society of Transplantation infectious diseases community of Practice","volume":"33","author":"Wolfe","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/TP.0000000000001848","article-title":"Perioperative antibiotic prophylaxis to prevent surgical site infections in solid organ transplantation","volume":"102","author":"Anesi","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100937_bb0215","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1600-6143.2008.02186.x","article-title":"Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex","volume":"8","author":"Alexander","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0220","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/thx.2007.089458","article-title":"Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres","volume":"63","author":"Boussaud","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.trre.2025.100937_bb0225","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.healun.2010.06.007","article-title":"Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience","volume":"29","author":"De Soyza","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/TP.0000000000003231","article-title":"Risk factors and impact of perioperative prophylaxis on the risk of extended-spectrum beta-lactamase-producing Enterobacteriaceae-related infection among carriers following liver transplantation","volume":"105","author":"Logre","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100937_bb0235","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cmi.2020.12.016","article-title":"Oral decontamination with colistin plus neomycin in solid organ transplant recipients colonized by multidrug-resistant Enterobacterales: a multicentre, randomized, controlled, open-label, parallel-group clinical trial","volume":"27","author":"Farinas","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13599","article-title":"Clinical prediction tool for extended-spectrum beta-lactamase-producing enterobacterales as the etiology of a bloodstream infection in solid organ transplant recipients","volume":"23","author":"Wang","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0245","article-title":"Bloodstream infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance (2016-21)","volume":"6","author":"Adelman","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13756-021-00918-7","article-title":"Temporal trends, risk factors and outcomes of infections due to extended-spectrum beta-lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018","volume":"10","author":"Kohler","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.trre.2025.100937_bb0255","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.2147\/IDR.S269033","article-title":"Risk factors of extended-Spectrum Beta-lactamases-producing Escherichia coli community acquired urinary tract infections: a systematic review","volume":"13","author":"Larramendy","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0260","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jhin.2023.09.017","article-title":"Predictors for onset of extended-spectrum beta-lactamase-producing Escherichia coli-induced bacteraemia: a systematic review and meta-analysis","volume":"142","author":"Namikawa","year":"2023","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0265","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/cid\/ciaa190","article-title":"Risk factors for extended-Spectrum beta-lactamase-producing Enterobacterales bloodstream infection among solid-organ transplant recipients","volume":"72","author":"Anesi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0270","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1600-6143.2008.02197.x","article-title":"Risk factors for infection with extended-spectrum and AmpC beta-lactamase-producing gram-negative rods in renal transplantation","volume":"8","author":"Linares","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134737","article-title":"Urinary tract infections in kidney transplant patients due to Escherichia coli and Klebsiella pneumoniae-producing extended-Spectrum beta-lactamases: risk factors and molecular epidemiology","volume":"10","author":"Espinar","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.trre.2025.100937_bb0280","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab013","article-title":"PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales","volume":"3","author":"Paterson","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0285","first-page":"438","article-title":"Optimizing therapy of bloodstream infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"25","author":"Gudiol","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.trre.2025.100937_bb0290","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.idc.2024.03.008","article-title":"Diagnosing and managing urinary tract infections in kidney transplant recipients","volume":"38","author":"McAteer","year":"2024","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.trre.2025.100937_bb0295","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01102-21","article-title":"Propensity score and desirability of outcome ranking analysis of Ertapenem for treatment of nonsevere Bacteremic urinary tract infections due to extended-Spectrum-Beta-lactamase-producing Enterobacterales in kidney transplant recipients","volume":"65","author":"Gutierrez-Gutierrez","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0300","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00287-22","article-title":"Thirty-day mortality rates in patients with extended-Spectrum beta-lactamase-producing Enterobacterales bacteremia receiving Ertapenem versus other Carbapenems","volume":"66","author":"Park","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0305","doi-asserted-by":"crossref","first-page":"41","DOI":"10.37201\/req\/s03.10.2022","article-title":"Controversies in the management of ESBL-producing Enterabacterales. Clinical implications","volume":"35","author":"Maseda","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.trre.2025.100937_bb0310","article-title":"Evaluation of Oral amoxicillin\/Clavulanate for urinary tract infections caused by ceftriaxone non-susceptible Enterobacterales","volume":"12","author":"Salam","year":"2024","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.trre.2025.100937_bb0315","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-Tazobactam vs Meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2025.100937_bb0320","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/QCO.0000000000000789","article-title":"Role of new antibiotics in extended-spectrum beta-lactamase","volume":"34","author":"Bassetti","year":"2021","journal-title":"AmpC- Infections Curr Opin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0325","article-title":"Global evaluation of the antibacterial activity of Ceftolozane\/Tazobactam against ESBLs-producing Escherichia coli and Klebsiella pneumoniae: a systematic review and meta-analysis","volume":"10","author":"Rahim Khorasani","year":"2023","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0330","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/QCO.0000000000000685","article-title":"Treatment of extended-spectrum beta-lactamases infections: what is the current role of new beta-lactams\/beta-lactamase inhibitors?","volume":"33","author":"Bassetti","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0335","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01052-20","article-title":"Is ceftazidime\/avibactam an option for serious infections due to extended-Spectrum-beta-lactamase- and AmpC-producing Enterobacterales?: a systematic review and Meta-analysis","volume":"65","author":"Isler","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0340","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jgar.2024.04.014","article-title":"Evaluation of the activity of cefepime\/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates","volume":"38","author":"Morrissey","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0345","article-title":"Piperacillin\/tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis","author":"Onorato","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.trre.2025.100937_bb0350","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10096-023-04715-5","article-title":"Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections","volume":"43","author":"Herrmann","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0355","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijid.2023.07.004","article-title":"Cefepime vs carbapenems for treating third-generation cephalosporin-resistant AmpC beta-lactamase-hyperproducing Enterobacterales bloodstream infections: a multicenter retrospective study","volume":"134","author":"Hoellinger","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0360","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.trre.2025.100937_bb0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10096-019-03705-w","article-title":"Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriales","volume":"39","author":"Kim","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0370","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/jac\/dku215","article-title":"The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli","volume":"69","author":"Park","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0375","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0380","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02165-18","article-title":"A systematic review of single-dose aminoglycoside therapy for urinary tract infection: is it time to resurrect an old strategy?","volume":"63","author":"Goodlet","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0385","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1517\/14740330802410462","article-title":"The epidemiology of drug-induced disorders: the kidney","volume":"7","author":"Taber","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.trre.2025.100937_bb0390","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/ajt.15614","article-title":"Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients-results of a Spanish multicenter cohort","volume":"20","author":"Lopez-Medrano","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0395","article-title":"Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: results from a Spanish multicenter cohort","volume":"95","author":"Ruiz-Ruigomez","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0400","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of Fosfomycin for the treatment of multidrug-resistant Escherichia coli Bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.trre.2025.100937_bb0405","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/cid\/cix991","article-title":"Risks of infection and mortality among patients colonized with Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: validation of scores and proposal for management","volume":"66","author":"Cano","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0410","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Gutierrez-Gutierrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0415","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijantimicag.2019.07.017","article-title":"External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance","volume":"54","author":"Machuca","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0420","article-title":"Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: the impact of cytomegalovirus disease and lymphopenia","author":"Perez-Nadales","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0425","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ajt.2023.03.011","article-title":"Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae","volume":"23","author":"Perez-Nadales","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100937_bb0430","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13881","article-title":"Extended-spectrum beta-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: recent trends in epidemiology and therapeutic approaches","volume":"24","author":"Perez-Nadales","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0435","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14036","article-title":"Validation of the INCREMENT-SOT-CPE score in a large cohort of liver transplant recipients with carbapenem-resistant Enterobacterales infection","volume":"25","author":"Rinaldi","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0440","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0445","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0450","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21037\/atm.2019.10.40","article-title":"Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli","volume":"8","author":"Chen","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.trre.2025.100937_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107152","article-title":"Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: focus on solid organ transplantation recipients","volume":"63","author":"Hu","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.726282","article-title":"Analysis of risk factors for Carbapenem-resistant Klebsiella pneumoniae infection and its effect on the outcome of early infection after kidney transplantation","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.trre.2025.100937_bb0465","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.2147\/IDR.S343505","article-title":"Efficacy of ceftazidime-avibactam in the treatment of Carbapenem-resistant Klebsiella pneumoniae infection after kidney transplantation","volume":"14","author":"Zhang","year":"2021","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0470","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jac\/dkac049","article-title":"Impact of ceftazidime\/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)","volume":"77","author":"Caston","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0475","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00449-17","article-title":"Multicenter study of outcomes with ceftazidime-avibactam in patients with Carbapenem-resistant Enterobacteriaceae infections","volume":"61","author":"King","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0480","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0485","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0495","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13510","article-title":"Treatment of invasive IMP-4 Enterobacter cloacae infection in transplant recipients using ceftazidime\/avibactam with aztreonam: a case series and literature review","volume":"23","author":"Cairns","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0500","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus Aztreonam in patients with bloodstream infections caused by Metallo-beta-lactamase-producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0505","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/cid\/cix387","article-title":"Application of \u201cprecision medicine\u201d through the molecular characterization of extensively drug-resistant Klebsiella pneumoniae in a multivisceral transplant patient","volume":"65","author":"Rosa","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0510","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0515","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0520","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00228-023-03609-x","article-title":"Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for phase IIa and phase III evaluation","volume":"80","author":"Das","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.trre.2025.100937_bb0525","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of Meropenem-Vaborbactam versus best-available therapy in patients with Carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.trre.2025.100937_bb0530","article-title":"Cefiderocol-based combination therapy for \u201cDifficult-to-Treat\u201d gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.trre.2025.100937_bb0535","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00948-19","article-title":"Coinfections of two strains of NDM-1- and OXA-232-coproducing Klebsiella pneumoniae in a kidney transplant patient","volume":"64","author":"Contreras","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0540","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13780","article-title":"Carbapenemase-producing Enterobacterales in solid organ transplantation: tip of the iceberg?","volume":"24","author":"Molina","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0545","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciab511","article-title":"Rapid development of Cefiderocol resistance in Carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the Catecholate Siderophore receptor cirA","volume":"74","author":"Klein","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0550","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1399-3062.2011.00688.x","article-title":"Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation","volume":"14","author":"Bergamasco","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0555","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13199","article-title":"Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: a retrospective study","volume":"22","author":"Chen","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0560","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.transproceed.2014.09.160","article-title":"Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study","volume":"46","author":"Mouloudi","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100937_bb0565","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of Eravacycline vs Meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0570","article-title":"Tigecycline treatment in a liver transplant infant with carbapenem-resistant Escherichia coli infection: case report","volume":"98","author":"Yang","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.trre.2025.100937_bb0575","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/nep.13594","article-title":"Beware of drug interaction between tigecycline and tacrolimus","volume":"25","author":"Chow","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trre.2025.100937_bb0580","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/phar.1883","article-title":"Effectiveness and safety of Tigecycline compared with other broad-Spectrum antimicrobials in abdominal solid organ transplant recipients with Polymicrobial intraabdominal infections","volume":"37","author":"Liebenstein","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.trre.2025.100937_bb0585","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12879-018-3103-z","article-title":"Tigecycline-induced acute pancreatitis in a renal transplant patient: a case report and literature review","volume":"18","author":"Lin","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0590","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13593","article-title":"A case report of tigecycline induced acute pancreatitis in a renal transplant patient and review of the literature: should we avoid tigecycline in patients on calcineurin inhibitors?","volume":"23","author":"Yazirli","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0595","article-title":"Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis","volume":"34","author":"Sastre-Femenia","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.trre.2025.100937_bb0600","article-title":"In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent beta-lactam\/beta-lactamase inhibitor combinations","volume":"12","author":"Santerre Henriksen","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.trre.2025.100937_bb0605","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1093\/jac\/dkac298","article-title":"In vitro activity of imipenem\/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)","volume":"77","author":"Hernandez-Garcia","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0610","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jac\/dkae126","article-title":"In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain","volume":"79","author":"Maruri-Aransolo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0615","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","article-title":"Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia","volume":"75","author":"Delgado-Valverde","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0620","doi-asserted-by":"crossref","first-page":"302","DOI":"10.37201\/req\/007.2023","article-title":"Activity of imipenem\/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020","volume":"36","author":"Garcia-Fernandez","year":"2023","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.trre.2025.100937_bb0625","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2021.06.011","article-title":"In vitro activity of cefiderocol and comparators against isolates of gram-negative bacterial pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Spain","volume":"26","author":"Cercenado","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0630","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.11.015","article-title":"The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-a meta-analysis of randomized controlled trials","volume":"55","author":"Cheng","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106278","article-title":"Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)","volume":"57","author":"Johnson","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0645","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus Doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0650","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0655","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0660","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/Cilastatin\/Relebactam versus piperacillin\/Tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0665","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs Polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0670","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/Relebactam vs Colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0675","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02203-19","article-title":"Comparison of treatment outcomes between analysis populations in the RESTORE-IMI 1 phase 3 trial of imipenem-Cilastatin-Relebactam versus Colistin plus imipenem-Cilastatin in patients with imipenem-nonsusceptible bacterial infections","volume":"64","author":"Kaye","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0680","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jiph.2022.08.020","article-title":"Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: a multicenter retrospective study","volume":"15","author":"Hakeam","year":"2022","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.trre.2025.100937_bb0685","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/00221309.2019.1656163","article-title":"The effect of educational priming on face recognition from a silver alert","volume":"147","author":"Gier","year":"2020","journal-title":"J Gen Psychol"},{"key":"10.1016\/j.trre.2025.100937_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105889","article-title":"Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis","volume":"55","author":"Chien","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0695","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-Tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0700","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0705","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107134","article-title":"Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant gram-negative organisms: a real-life experience","volume":"63","author":"Meschiari","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0715","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.2147\/IDR.S475462","article-title":"Effectiveness and safety of Cefiderocol in clinical Practice for treatment of patients with gram-negative bacterial infections: US interim results of the PROVE study","volume":"17","author":"Clancy","year":"2024","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0720","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant gram-negative bacteria: an Italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0725","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40121-023-00776-3","article-title":"Real-life data on the effectiveness and safety of Cefiderocol in severely infected patients: a case series","volume":"12","author":"Fendian","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.trre.2025.100937_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106818","article-title":"Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant gram-negative bacteria","volume":"62","author":"de la Fuente","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0735","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol treatment for patients with multidrug- and Carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0740","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01474-23","article-title":"Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-beta-lactamase (Bla(VIM)): infection management and molecular analysis","volume":"68","author":"Vega","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0745","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","article-title":"In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European gram-negative and gram-positive clinical isolates","volume":"45","author":"Testa","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0750","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/jac\/dkae263","article-title":"Impact of chromosomally encoded resistance mechanisms and transferable beta-lactamases on the activity of cefiderocol and innovative beta-lactam\/beta-lactamase inhibitor combinations against Pseudomonas aeruginosa","volume":"79","author":"Gonzalez-Pinto","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0755","article-title":"Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.trre.2025.100937_bb0760","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0765","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jgar.2022.05.011","article-title":"In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance","volume":"30","author":"Findlay","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0770","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jac\/42.6.793","article-title":"Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii","volume":"42","author":"Corbella","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0775","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jinf.2008.04.002","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0780","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/00365540600951184","article-title":"High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii","volume":"39","author":"Betrosian","year":"2007","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0785","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2020.08.021","volume":"24","author":"Liu","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0790","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-Sulbactam combinations combat Polymyxin-resistant Acinetobacter baumannii in a hollow-Fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0795","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug-Resistant A. baumannii: a review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.trre.2025.100937_bb0800","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/mdr.2022.0248","article-title":"Tigecycline-containing regimens and multi drug-resistant Acinetobacter baumannii: a systematic review and Meta-analysis","volume":"29","author":"Sodeifian","year":"2023","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0805","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00479-22","article-title":"Clinical outcomes of Eravacycline in patients treated predominately for Carbapenem-resistant Acinetobacter baumannii","volume":"10","author":"Alosaimy","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.trre.2025.100937_bb0810","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1186\/s12879-024-09899-5","article-title":"Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis","volume":"24","author":"Zhan","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0815","article-title":"Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis","volume":"63","author":"Gatti","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.trre.2025.100937_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.01.012","article-title":"Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis","volume":"88","author":"Onorato","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0825","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab026","article-title":"Colistin nephrotoxicity: Meta-analysis of randomized controlled trials","volume":"8","author":"Eljaaly","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9061154","article-title":"Nebulized Colistin in ventilator-associated pneumonia and Tracheobronchitis: historical background, pharmacokinetics and perspectives","volume":"9","author":"Zhu","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.trre.2025.100937_bb0835","article-title":"Use of high-dose nebulized Colistimethate in patients with Colistin-only susceptible Acinetobacter baumannii VAP: clinical, pharmacokinetic and microbiome features","volume":"12","author":"De Pascale","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.trre.2025.100937_bb0840","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac040","article-title":"Clinical challenges treating Stenotrophomonas maltophilia infections: an update","volume":"4","author":"Mojica","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.trre.2025.100937_bb0845","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eimc.2022.06.004","article-title":"Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant gram-negative bacteria","volume":"41","author":"Pintado","year":"2023","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"10.1016\/j.trre.2025.100937_bb0850","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1128\/AAC.01324-13","article-title":"Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections","volume":"58","author":"Wang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0855","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.cmi.2018.11.008","article-title":"Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis","volume":"25","author":"Ko","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2025.100937_bb0860","article-title":"Stenotrophomonas maltophilia infections: a systematic review and meta-analysis of comparative efficacy of available treatments, with critical assessment of novel therapeutic options","volume":"12","author":"Maraolo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.trre.2025.100937_bb0865","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/jac\/dkv456","article-title":"Monotherapy with minocycline or trimethoprim\/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections","volume":"71","author":"Hand","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0870","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/10600280231201850","article-title":"Trimethoprim\/sulfamethoxazole vs minocycline for the treatment of nonurinary Monomicrobial Stenotrophomonas maltophilia infections in hospitalized patients","volume":"58","author":"Hevia","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.trre.2025.100937_bb0875","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1093\/jac\/dkw327","article-title":"Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections","volume":"71","author":"Jacobson","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"In vitro activity of Cefiderocol, a novel Siderophore cephalosporin, against gram-negative Bacilli isolated from patients in Canadian intensive care units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0885","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01433-20","article-title":"Antimicrobial activity of Aztreonam-avibactam and comparator agents when tested against a large collection of contemporary Stenotrophomonas maltophilia isolates from medical centers worldwide","volume":"64","author":"Sader","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0890","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/jac\/dkz116","article-title":"Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia","volume":"74","author":"Shah","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2025.100937_bb0895","article-title":"Combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia infections: a systematic review and Meta-analysis","volume":"11","author":"Prawang","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.trre.2025.100937_bb0900","article-title":"Description, clinical impact and early outcome of S. maltophilia respiratory tract infections after lung transplantation, a retrospective observational study","volume":"86","author":"Pilmis","year":"2024","journal-title":"Respir Med Res"},{"key":"10.1016\/j.trre.2025.100937_bb0905","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13613-023-01144-7","article-title":"Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study","volume":"13","author":"Chen","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.trre.2025.100937_bb0910","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13896","article-title":"Shorter is better: the case for short antibiotic courses for common infections in solid organ transplant recipients","volume":"24","author":"Imlay","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0915","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13868","article-title":"Comparison of short-course antibiotic therapy of 6 or less days with a longer treatment in patients with cholangitis after liver transplantation","volume":"24","author":"Ferstl","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2025.100937_bb0920","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1111\/tri.14144","article-title":"Short versus prolonged antibiotic treatment for complicated urinary tract infection after kidney transplantation","volume":"34","author":"Avni-Nachman","year":"2021","journal-title":"Transpl Int"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:05:34Z","timestamp":1752599134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X25000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":184,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0955470X25000370"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2025.100937","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of multidrug-resistant gram-negative bacilli infections in adult solid organ transplant recipients: GESITRA-IC\/SEIMC, CIBERINFEC, and SET recommendations update.","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2025.100937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100937"}}